{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:39:33Z","timestamp":1768639173362,"version":"3.49.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Cardiovascular Imaging"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:p><jats:bold><jats:italic>Background\u2014<\/jats:italic><\/jats:bold>The pharmacological stress agents adenosine and dipyridamole are contraindicated in asthma patients because of the risk of adenosine receptor-mediated bronchospasm. Binodenoson, a selective adenosine A<jats:sub>2A<\/jats:sub>receptor agonist, produces maximal coronary hyperemia during pharmacological stress testing yet has a low affinity for the adenosine A<jats:sub>1<\/jats:sub>, A<jats:sub>2B<\/jats:sub>, and A<jats:sub>3<\/jats:sub>receptors that are probably responsible for bronchospasm. This study was conducted to assess the safety of binodenoson in 87 healthy young adult volunteers with documented mild, intermittent asthma.<\/jats:p><jats:p><jats:bold><jats:italic>Methods and Results\u2014<\/jats:italic><\/jats:bold>This study consisted of a dose-escalating, single-blinded phase and a placebo-controlled, double-blinded phase conducted in healthy, young adults with documented mild, intermittent, asthma. In the single-blinded phase, 3 sequential cohorts of 8 subjects received intravenous binodenoson (0.5, 1.0, and 1.5 \u03bcg\/kg). In the double-blinded phase, commenced after medical review of results from the single-blinded phase, subjects were randomly assigned 2:1 to either binodenoson 1.5 \u03bcg\/kg (n=41) or placebo (n=22). The primary end point was clinically significant bronchoconstriction, defined as a decrease in forced expiratory volume in 1 second of \u226520% from the preinjection measure. Secondary safety end points were changes from preinjection measure in forced expiratory volume in 1 second, forced vital capacity, and forced expiratory flow during the middle 50% of the forced vital capacity; vital signs; pulse oximetry; and adverse events. Binodenoson caused no clinically significant bronchoconstriction or alterations in pulmonary function parameters and transiently increased heart rate and systolic blood pressure. The most common treatment-emergent adverse events were tachycardia, dizziness, and flushing.<\/jats:p><jats:p><jats:bold><jats:italic>Conclusions\u2014<\/jats:italic><\/jats:bold>Binodenoson was safe, well tolerated, and caused no clinically significant bronchoconstriction or pulmonary responses in a small population of healthy subjects with mild, intermittent asthma.<\/jats:p>","DOI":"10.1161\/circimaging.108.817932","type":"journal-article","created":{"date-parts":[[2009,9,18]],"date-time":"2009-09-18T05:35:31Z","timestamp":1253252131000},"page":"492-498","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Safety of Binodenoson, a Selective Adenosine A<sub>2A<\/sub>Receptor Agonist Vasodilator Pharmacological Stress Agent, in Healthy Subjects With Mild Intermittent Asthma"],"prefix":"10.1161","volume":"2","author":[{"given":"John J.","family":"Murray","sequence":"first","affiliation":[{"name":"From Vanderbilt University Medical Center (J.J.M.), Nashville, Tenn; Iowa Clinical Research Corporation (J.M.W.), Iowa City, Iowa; Virginia Commonwealth University (L.B.S.), Richmond, Va; University of Wisconsin Medical School (W.W.B.), Madison, Wis; National Jewish Medical and Research Center (R.K.K.), Denver, Colo; the University of South Florida (R.F.L.), Tampa, Fla; MetroHealth Medical Center (E.R.M.), Cleveland, Ohio; and King Pharmaceuticals Research and Development, Inc (G.C.P., R.J.B.), Cary..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Weiler","sequence":"additional","affiliation":[{"name":"From Vanderbilt University Medical Center (J.J.M.), Nashville, Tenn; Iowa Clinical Research Corporation (J.M.W.), Iowa City, Iowa; Virginia Commonwealth University (L.B.S.), Richmond, Va; University of Wisconsin Medical School (W.W.B.), Madison, Wis; National Jewish Medical and Research Center (R.K.K.), Denver, Colo; the University of South Florida (R.F.L.), Tampa, Fla; MetroHealth Medical Center (E.R.M.), Cleveland, Ohio; and King Pharmaceuticals Research and Development, Inc (G.C.P., R.J.B.), Cary..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence B.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"From Vanderbilt University Medical Center (J.J.M.), Nashville, Tenn; Iowa Clinical Research Corporation (J.M.W.), Iowa City, Iowa; Virginia Commonwealth University (L.B.S.), Richmond, Va; University of Wisconsin Medical School (W.W.B.), Madison, Wis; National Jewish Medical and Research Center (R.K.K.), Denver, Colo; the University of South Florida (R.F.L.), Tampa, Fla; MetroHealth Medical Center (E.R.M.), Cleveland, Ohio; and King Pharmaceuticals Research and Development, Inc (G.C.P., R.J.B.), Cary..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W.","family":"Busse","sequence":"additional","affiliation":[{"name":"From Vanderbilt University Medical Center (J.J.M.), Nashville, Tenn; Iowa Clinical Research Corporation (J.M.W.), Iowa City, Iowa; Virginia Commonwealth University (L.B.S.), Richmond, Va; University of Wisconsin Medical School (W.W.B.), Madison, Wis; National Jewish Medical and Research Center (R.K.K.), Denver, Colo; the University of South Florida (R.F.L.), Tampa, Fla; MetroHealth Medical Center (E.R.M.), Cleveland, Ohio; and King Pharmaceuticals Research and Development, Inc (G.C.P., R.J.B.), Cary..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit K.","family":"Katial","sequence":"additional","affiliation":[{"name":"From Vanderbilt University Medical Center (J.J.M.), Nashville, Tenn; Iowa Clinical Research Corporation (J.M.W.), Iowa City, Iowa; Virginia Commonwealth University (L.B.S.), Richmond, Va; University of Wisconsin Medical School (W.W.B.), Madison, Wis; National Jewish Medical and Research Center (R.K.K.), Denver, Colo; the University of South Florida (R.F.L.), Tampa, Fla; MetroHealth Medical Center (E.R.M.), Cleveland, Ohio; and King Pharmaceuticals Research and Development, Inc (G.C.P., R.J.B.), Cary..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Lockey","sequence":"additional","affiliation":[{"name":"From Vanderbilt University Medical Center (J.J.M.), Nashville, Tenn; Iowa Clinical Research Corporation (J.M.W.), Iowa City, Iowa; Virginia Commonwealth University (L.B.S.), Richmond, Va; University of Wisconsin Medical School (W.W.B.), Madison, Wis; National Jewish Medical and Research Center (R.K.K.), Denver, Colo; the University of South Florida (R.F.L.), Tampa, Fla; MetroHealth Medical Center (E.R.M.), Cleveland, Ohio; and King Pharmaceuticals Research and Development, Inc (G.C.P., R.J.B.), Cary..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"E.R.","family":"McFadden","sequence":"additional","affiliation":[{"name":"From Vanderbilt University Medical Center (J.J.M.), Nashville, Tenn; Iowa Clinical Research Corporation (J.M.W.), Iowa City, Iowa; Virginia Commonwealth University (L.B.S.), Richmond, Va; University of Wisconsin Medical School (W.W.B.), Madison, Wis; National Jewish Medical and Research Center (R.K.K.), Denver, Colo; the University of South Florida (R.F.L.), Tampa, Fla; MetroHealth Medical Center (E.R.M.), Cleveland, Ohio; and King Pharmaceuticals Research and Development, Inc (G.C.P., R.J.B.), Cary..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn C.","family":"Pixton","sequence":"additional","affiliation":[{"name":"From Vanderbilt University Medical Center (J.J.M.), Nashville, Tenn; Iowa Clinical Research Corporation (J.M.W.), Iowa City, Iowa; Virginia Commonwealth University (L.B.S.), Richmond, Va; University of Wisconsin Medical School (W.W.B.), Madison, Wis; National Jewish Medical and Research Center (R.K.K.), Denver, Colo; the University of South Florida (R.F.L.), Tampa, Fla; MetroHealth Medical Center (E.R.M.), Cleveland, Ohio; and King Pharmaceuticals Research and Development, Inc (G.C.P., R.J.B.), Cary..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Barrett","sequence":"additional","affiliation":[{"name":"From Vanderbilt University Medical Center (J.J.M.), Nashville, Tenn; Iowa Clinical Research Corporation (J.M.W.), Iowa City, Iowa; Virginia Commonwealth University (L.B.S.), Richmond, Va; University of Wisconsin Medical School (W.W.B.), Madison, Wis; National Jewish Medical and Research Center (R.K.K.), Denver, Colo; the University of South Florida (R.F.L.), Tampa, Fla; MetroHealth Medical Center (E.R.M.), Cleveland, Ohio; and King Pharmaceuticals Research and Development, Inc (G.C.P., R.J.B.), Cary..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","unstructured":"IMV. 2005 Nuclear Medicine Census Market Summary Report. Des Plaines IL: IMV Medical Information Division 2006."},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-2998(99)80018-X"},{"key":"e_1_3_2_3_2","unstructured":"Adenoscan [package insert]. Deerfield IL: Astellas Pharma US Inc; 2005."},{"key":"e_1_3_2_4_2","unstructured":"Persantine [package insert]. Bedford OH: Bedford Laboratories; 2006."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.all.0000199797.02423.78"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.01132002"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0022-3565(24)37317-3","volume":"284","year":"1998","unstructured":"Belardinelli L, Shryock JC, Snowdy S, Zhang Y, Monopoli A, Lozza G, Ongini E, Olsson RA, Dennis DM. The A2A adenosine receptor mediates coronary vasodilation. J Pharmacol Exp Ther. 1998; 284: 1066\u20131073.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(94)90424-3"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.4065\/70.4.331"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.81.4.2107985"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-3581(96)90076-8"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706272"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2299(199704)40:4<313::AID-DDR5>3.0.CO;2-M"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000114523.03312.7d"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.12.086"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.1.ats11-99"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(02)80002-1"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000034670.06526.15"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/096032719401300407"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.4065\/74.4.339"},{"key":"e_1_3_2_21_2","first-page":"436","volume":"128","year":"2007","unstructured":"van Gaal WJ, Couthino B, Chan M, Allman KC. The safety and tolerability of adenosine in patients with obstructive airways disease. Int J Cardiol. 2007; 128: 436\u2013438.","journal-title":"Int J Cardiol"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2007.07.013"},{"key":"e_1_3_2_23_2","first-page":"737","volume":"35","year":"1994","unstructured":"Verani MS. Dobutamine myocardial perfusion imaging. J Nucl Med. 1994; 35: 737\u2013739.","journal-title":"J Nucl Med"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.095323"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199203000-00025"}],"container-title":["Circulation: Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCIMAGING.108.817932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:18:58Z","timestamp":1739344738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCIMAGING.108.817932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1161\/CIRCIMAGING.108.817932"],"URL":"https:\/\/doi.org\/10.1161\/circimaging.108.817932","relation":{},"ISSN":["1941-9651","1942-0080"],"issn-type":[{"value":"1941-9651","type":"print"},{"value":"1942-0080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"2009-09-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}